BACKGROUND
In 2015, prescription opioids and heroin overdoses resulted in more than 30,000 fatalities in the United States (US). 1 The preventable deaths in these young and relatively healthy victims have contributed to the expansion of a scarce donor organ pool for critically ill patients waitlisted for solid organ transplantation due to single/multi-organ failure refractory to medical treatment options. 2 The aim of this study was to evaluate the contribution and outcomes associated with the utilization of drug overdose (DO) donors on solid organ transplantation in the US.
METHODS
We performed a retrospective analysis using the United Network for Organ Sharing (UNOS) database from January 1, 2000, to December 31, 2016, to study the annual trends in the etiology of death leading to organ donation for kidney, liver, heart, and lung transplantation in the US. In addition, we compared donor demographics and characteristics of DO organ donors versus all other causes of organ donation. Kaplan-Meir survival analyses were performed to determine post-transplant patient survival rates among liver and kidney transplant recipients. Due to the small sample size, post-transplant outcomes in heart and lung transplant recipients were not analyzed. Using the Center for Disease Control (CDC) WONDER database, crude cause-specific mortality rates (per 100,000 persons) due to DO were determined.
3 SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC, USA) was used.
RESULTS
From 2000 to 2016, a total of 290,102 adult deceased donor-related kidney (50.6%), liver (29.8%), heart (11.2%), and lung (8.4%) transplant surgeries were performed in the US. Of these, 15,359 (5.3%) donors died from DO. The annual number and proportion of solid organ transplants utilizing DO donors have rapidly increased since 2012 as depicted in Fig. 1a , b. Compared to all other causes of organ donation, donors due to DO were significantly younger with a higher prevalence of Caucasians and hepatitis C virus (HCV) seropositivity (Table 1) . More importantly, DO-related liver and kidney donor organs were associated with a significantly higher 1-year patient survival rate (Table 1 ). In 2016, over 25% of solid organ transplants in UNOS regions spanning the Northeast and Mid-Atlantic states (UNOS regions 1, 2, and 9) utilized DO donors. These geographic areas in the US also demonstrated the highest cause-specific mortality rates from DO (34.9 per 100,000 persons) in 2016. Among HCV seropositive donor organ pool, allografts procured from DO donors increased by 24% annually, accounted for nearly 50% of all HCV seropositive donor organs in 2016, and were noted to have a lower liver donor risk and kidney donor profile indices compared to all other allografts. In a sub-analysis, observed 1-year survival rates in liver transplant recipients with HCV seropositive DO organs were statistically comparable to non-HCV DO organs (HCV seropositive 92.5% vs. non-HCV DO 91.8%, P = 0.34) following the introduction of direct-acting antiviral (DAA) therapy in late 2013.
DISCUSSION
Deaths related to DO have now become a significant contributor to the expansion of the deceased donor organ pool for solid organ transplantation in the US. Noted limitations of this study include details related to drug exposure-type/dosage/ duration/timing and the retrospective design of the study. The unfortunate reality is that DO has led to the tragic loss of our nation's youth. However, these young, otherwise healthy, donors have lower donor risk indices, leading to higher liver and kidney transplant survival rates compared to all other donors. With the availability of efficacious DAA agents for 
